(NASDAQ: CSTL) Castle Biosciences's forecast annual revenue growth rate of 8.43% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.56%.
Castle Biosciences's revenue in 2026 is $344,229,000.On average, 10 Wall Street analysts forecast CSTL's revenue for 2026 to be $10,481,733,855, with the lowest CSTL revenue forecast at $10,031,900,829, and the highest CSTL revenue forecast at $10,862,590,501. On average, 10 Wall Street analysts forecast CSTL's revenue for 2027 to be $11,811,907,653, with the lowest CSTL revenue forecast at $11,179,822,384, and the highest CSTL revenue forecast at $12,465,399,385.
In 2028, CSTL is forecast to generate $13,014,831,925 in revenue, with the lowest revenue forecast at $12,313,175,652 and the highest revenue forecast at $13,630,862,347.